MIR377 is a microRNA that is overexpressed in GH-, TSH-, and PRL-secreting adenomas [PMC7652879]. It has been shown to influence myocardial regeneration and angiogenesis by targeting genes involved in inflammation, oxidative stress, and angiogenesis [PMC7527411]. Additionally, MIR377 has been found to regulate metastatic capability by inhibiting the process of epithelial-mesenchymal transition (EMT) and inactivating the Wnt/β-catenin pathway [PMC9212183]. It has also been implicated in gastric cancer cell proliferation [PMC5795907]. MIR377 interacts with various genes, including NEAT1, pseudogenes (RPL7P27, RPL7P27, RP11-618N24, SPCS2P1, RP11-209D20, RPL27AP5, MTND2P28, RP11-618N24, NSUN5P1, FTLP10), miRNAs (MIR204,MIR449A,MIR506,MIR335,MIR181D,MIR107), protein-coding genes,rRNAs ,snRNAs ,and tRNA [PMC9730017]. Furthermore,it is upregulated after IFN-γ stimulation [PMC8010072]. MIR377 has also been studied in the context of glioma-conditioned endothelial cells (GECs) and its possible regulatory relationships with piR-DQ590027,MIR17HG ,miR-153,and FOXR2 on the permeability of glioma-conditioned normal blood-brain barrier (BBB) [PMC6180493]. Additionally,luteolin treatment downregulated MIR377 expression in glioma cells[PMC4791268]. Overall,Mir377 plays a role in various biological processes including adenoma development and metastasis regulation.